591 related articles for article (PubMed ID: 31201481)
21. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
[TBL] [Abstract][Full Text] [Related]
22. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
23. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.
Silverman S; Viswanathan HN; Yang YC; Wang A; Boonen S; Ragi-Eis S; Fardellone P; Gilchrist N; Lips P; Nevitt M; Palacios Gil-Antuñano S; Pavelka K; Revicki D; Simon J; Macarios D; Siris ES
Osteoporos Int; 2012 Apr; 23(4):1361-9. PubMed ID: 21769664
[TBL] [Abstract][Full Text] [Related]
24. Denosumab: A Review in Postmenopausal Osteoporosis.
Deeks ED
Drugs Aging; 2018 Feb; 35(2):163-173. PubMed ID: 29435849
[TBL] [Abstract][Full Text] [Related]
25. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
Ferrari S; Butler PW; Kendler DL; Miller PD; Roux C; Wang AT; Huang S; Wagman RB; Lewiecki EM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3450-3461. PubMed ID: 31125092
[TBL] [Abstract][Full Text] [Related]
26. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
27. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
28. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
[TBL] [Abstract][Full Text] [Related]
29. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
30. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
Bone HG; Chapurlat R; Brandi ML; Brown JP; Czerwinski E; Krieg MA; Mellström D; Radominski SC; Reginster JY; Resch H; Ivorra JA; Roux C; Vittinghoff E; Daizadeh NS; Wang A; Bradley MN; Franchimont N; Geller ML; Wagman RB; Cummings SR; Papapoulos S
J Clin Endocrinol Metab; 2013 Nov; 98(11):4483-92. PubMed ID: 23979955
[TBL] [Abstract][Full Text] [Related]
31. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
32. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
[TBL] [Abstract][Full Text] [Related]
33. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
Bolognese MA; Teglbjærg CS; Zanchetta JR; Lippuner K; McClung MR; Brandi ML; Høiseth A; Lakatos P; Moffett AH; Lorenc RS; Wang A; Libanati C
J Clin Densitom; 2013; 16(2):147-53. PubMed ID: 22521543
[TBL] [Abstract][Full Text] [Related]
34. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.
Dempster DW; Brown JP; Fahrleitner-Pammer A; Kendler D; Rizzo S; Valter I; Wagman RB; Yin X; Yue SV; Boivin G
J Clin Endocrinol Metab; 2018 Jul; 103(7):2498-2509. PubMed ID: 29672714
[TBL] [Abstract][Full Text] [Related]
35. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
36. Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.
Watts NB; Brown JP; Papapoulos S; Lewiecki EM; Kendler DL; Dakin P; Wagman RB; Wang A; Daizadeh NS; Smith S; Bone HG
J Bone Miner Res; 2017 Jul; 32(7):1481-1485. PubMed ID: 28277603
[TBL] [Abstract][Full Text] [Related]
37. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
[TBL] [Abstract][Full Text] [Related]
38. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
39. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
40. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
